8-K: Inari Medical Reports 23.3% Revenue Growth in Q1 2024, Raises Full-Year Guidance

Inari Medical announced a 23.3% year-over-year revenue increase for the first quarter of 2024, driven by increased adoption of their procedures and new products, and raised its full-year revenue guidance.

Summary

• Inari Medical reported a revenue of $143.2 million for the first quarter of 2024, a 23.3% increase compared to $116.2 million in the same quarter of 2023.
• The company's gross profit was $124.3 million, with a gross margin of 86.8%, slightly down from 88.2% in the prior year due to internationalization, new product costs, and product mix.
• Inari experienced a GAAP operating loss of $17.2 million in Q1 2024, compared to a $5.3 million loss in Q1 2023.
• Non-GAAP operating loss was $5.6 million in Q1 2024, compared to a $5.3 million non-GAAP operating loss in the same quarter of last year.
• The company's net loss for the quarter was $24.2 million, or $0.42 per share, compared to a net loss of $2.2 million, or $0.04 per share, in the same period last year.
• Inari has raised its full-year 2024 revenue guidance to $592.5 million to $602.5 million, reflecting a 20% to 22% growth over 2023, up from the previous guidance of $580 million to $595 million.
• The company expects to achieve sustained operating profitability in the first half of 2025.

Sentiment

Score: 7

Explanation: The document shows strong revenue growth and increased guidance, which are positive. However, the increased operating and net losses temper the overall sentiment. The company is on a path to profitability, but it's not there yet.

Positives

• Revenue growth was strong at 23.3% year-over-year, indicating increased market adoption of Inari's products.
• The company has raised its full-year revenue guidance, demonstrating confidence in future performance.
• Inari is making progress towards profitability, with expectations to reach sustained operating profitability in the first half of 2025.
• Emerging Therapies revenue showed very strong growth of 184.5% year-over-year.

Negatives

• The company experienced a larger GAAP operating loss of $17.2 million in Q1 2024 compared to $5.3 million in Q1 2023.
• Net loss increased significantly to $24.2 million, or $0.42 per share, compared to $2.2 million, or $0.04 per share, in the same period last year.
• Gross margin decreased slightly from 88.2% to 86.8% due to internationalization, new product costs, and product mix.

Risks

• The company's operating expenses increased significantly, driven by personnel-related costs and acquisition-related expenses.
• The company is still operating at a loss, although they expect to reach profitability in the first half of 2025.
• The company's future performance is subject to risks and uncertainties, as detailed in their SEC filings.

Future Outlook

Inari expects full year 2024 revenue of $592.5 million to $602.5 million, reflecting growth of approximately 20% to 22% over 2023, and anticipates reaching sustained operating profitability in the first half of 2025.

Management Comments

• Drew Hykes, CEO of Inari Medical, stated that the strong first quarter performance reflected crisp execution across their three growth pillars.
• He also mentioned the continued growth of their commercial engine and investment in clinical data, including the PEERLESS study.

Industry Context

Inari Medical operates in the medical device industry, specifically focusing on venous and other diseases. The company's growth is driven by the adoption of its innovative solutions and expansion into new markets. The results indicate a strong demand for their products and services within this sector.

Comparison to Industry Standards

• While Inari's revenue growth of 23.3% is strong, it's important to compare this to other medical device companies in the venous disease space. Companies like Boston Scientific and Medtronic, while much larger, also report growth in their respective segments.
• Inari's gross margin of 86.8% is very high, suggesting a premium pricing strategy and efficient manufacturing. This is a positive sign compared to many other medical device companies that often have lower gross margins.
• The operating loss, while concerning, is not uncommon for growth-stage medical device companies that are investing heavily in R&D and commercial expansion. Companies like Shockwave Medical, for example, have also experienced operating losses while scaling up.
• The company's focus on clinical data, such as the PEERLESS study, is a common strategy in the medical device industry to support product adoption and market penetration. This is similar to how companies like Edwards Lifesciences conduct clinical trials to support their products.

Stakeholder Impact

• Shareholders will likely react positively to the increased revenue guidance but may be concerned about the increased losses.
• Employees may benefit from the company's growth and expansion.
• Customers will have access to innovative medical solutions.
• Suppliers may see increased demand for their products and services.

Next Steps

• The company will present the PEERLESS study results in the second half of 2024.
• Inari will continue to focus on driving adoption of its products and expanding its commercial reach.
• The company will host a conference call to discuss the first quarter 2024 financial results.

Key Dates

Keywords

Inari Medical, Medical Devices, Venous Thromboembolism, Revenue Growth, Financial Results, Operating Loss, Gross Margin, Profitability, Guidance, Emerging Therapies